Research Idea
Research content for general circulation. Not individualized advice.Ā Methodology & Disclosures
Fiscal Q1 revenue rose 6% to $339 million, adjusted EPS beat estimates, and management raised revenue, EPS, free-cash-flow, and organic-growth guidance; shares gained 41.1% through August 20.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ā¢ Margin strength ā¢ Strong liquidity ā¢ Elevated leverage HAE shows healthy margins, strong cash generation, and solid liquidity, but elevated leverage and premium valuation limit upside.
Price Behavior
Key Price Behavior Insights: ā¢ Uptrend intact ā¢ Breakout support ā¢ Short-term extended Support Level: $87.00ā$88.00 Resistance Level: $91.34 HAE has rallied steadily over the last month, breaking above the $87.00ā$88.00 zone and nearing $91.34 resistance, but the fast move leaves it short-term extended and vulnerable to a pause.
Sentiment & News
Key News Insights: ā¢ Earnings Beat ā¢ Raised Guidance ā¢ International Exposure Haemonetics delivered a strong Q1 fiscal 2027 beat, raised full-year guidance on Plasma growth and cash generation, and added operational and board momentum despite some caution around international sales.
AI Summary
HAE now looks like a self-funding growth-and-repair story rather than a pure defensive med-tech name, with earnings beats, stronger plasma momentum, and solid free cash flow improving the caseābut after the re-rating, investors need continued execution on margins and deleveraging to justify further upside.
Description
Haemonetics Corporation develops and sells medical devices and software for plasma collection, blood center operations, and hospital transfusion and hemostasis management. Its product set includes automated and manual collection systems, donor and blood bank information platforms, and perioperative hemostasis and cell-salvage equipment, marketed through a mix of direct sales, distributors, and representatives. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 20 | Aug 27 | HAE | Haemonetics Corporation | Fiscal Q1 revenue rose 6% to $339 million, adjusted EPS beat estimates, and management raised revenue, EPS, free-cash-flow, and organic-growth guidance; shares gained 41.1% through August 20. | Active | +0.0% |